◼

News

Latest News

01.06.25
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer
View
12.18.24
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
View
11.20.24
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights
View
10.30.24
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
View
10.24.24
Septerna Prices Upsized Initial Public Offering
View

All News

Keep up to date with the world of Septerna

All
2025
2024
2023
2022

01.06.25

Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr.
Discover more

About Us

View

Pipeline

View

Platform

View

Get In Touch

250 East Grand Avenue 
South San Francisco, CA 94080
650-338-3533

General Inquiries:

Info@septerna.com

Investors & Media:

investors@septerna.com

© 2025 Septerna